Insulet (NASDAQ: PODD) reported Q3 EPS of $0.90, $0.12 better than the analyst estimate of $0.78. Revenue for the quarter came in at $543.9 million versus the consensus estimate of $518.76 million.

2024 Outlook:

Revenue Guidance (in constant currency):

For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 20% to 21% (previously 16% to 19%). Revenue growth ranges by product line are:

Total Omnipod of 21% to 22% (previously 18% to 21%)

U.S. Omnipod of 19% to 21% (previously 18% to 21%)
International Omnipod of 25% to 27% (previously 18% to 21%)

Drug Delivery of (10)% to (5)% (previously (50)% to (40)%)

For the quarter ending December 31, 2024, the Company expects revenue growth of 12% to 15%. Revenue growth ranges by product line are:

Total Omnipod of 13% to 16%

U.S. Omnipod of 9% to 12%5
International Omnipod of 30% to 33%

Drug Delivery of (20)% to (15)% (approximately $7 million to $8 million)

Gross Margin and Operating Margin Guidance:

For the year ending December 31, 2024, the Company now expects gross margin to be approximately 69% (previously 68% to 69%, closer to the high end).

For the year ending December 31, 2024, the Company is raising its expected operating margin by 50 basis points to approximately 14.5%.

For earnings history and earnings-related data on Insulet (PODD) click here.